RT Journal Article
SR Electronic
T1 Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Loreto, Peru
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.17.21249913
DO 10.1101/2021.01.17.21249913
A1 Álvarez-Antonio, Carlos
A1 Meza-Sánchez, Graciela
A1 Calampa, Carlos
A1 Casanova, Wilma
A1 Carey, Cristiam
A1 Alava, Freddy
A1 Rodríguez-Ferrucci, Hugo
A1 Quispe, Antonio M.
YR 2021
UL http://medrxiv.org/content/early/2021/01/20/2021.01.17.21249913.abstract
AB Background Detection of SARS-CoV-2 antibodies among people at risk is critical for understanding both the prior transmission of COVID-19 and vulnerability of the population to the continuing transmission and, when done serially, the intensity of ongoing transmission over an interval in a community. In this study, we estimated the seroprevalence of COVID-19 in a representative population-based cohort of Iquitos, one of the regions with the highest mortality rates from COVID-19 in Peru, where a devastating number of cases occurred in March 2020.Methods We conducted a population-based study of transmission tested each participant using the COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech and used survey analysis methods to estimate seroprevalence accounting for the sampling design effect and test performance characteristics. Here we report results from the baseline (13 to 18 July 2020) and the first month of follow-up (13 to 18 August 2020) study.Findings We enrolled a total of 716 participants and estimated seroprevalence of 70.0% (95% CI: 67.0%–73.4%), a test-re-test positivity of 65% (95% CI: 61.0%–68.3%), and an incidence of new exposures of 1.8% (95% CI: 0.9%–3.2%) data that suggest that transmission is ongoing but is occurring at low levels. We observed significant differences in the seroprevalence between age groups, with participants 18 to 29 years of age having lower seroprevalence than children <12 years of age (Prevalence ratio =0.85 [PR]; 95% CI: 0.73 – 0.98), suggesting that children were not refractory to infection in this setting.Interpretation Iquitos demonstrates one of the highest rates of seroprevalence of COVID-19 worldwide. Current data shows a limited case burden in Iquitos for the past seven months and suggests that these levels are sufficient to provide significant but incomplete herd immunity.Funding Dirección Regional de Salud de Loreto, DIRESA, Loreto, PeruCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was completely finance by Direccion Regional de Salud de Loreto, DIRESA, Loreto, PeruAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the hospital health network Institutional Scientific Committee and Institutional Review Board of the Regional Hospital, Iquitos, from Peru.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article.